The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Yargesa

100 milligram(s) Capsule, hard

Piramal Critical Care B.V.EU/1/17/1176/001

Main Information

Trade NameYargesa
Active SubstancesMiglustat
Strength100 milligram(s)
Dosage FormCapsule, hard
Licence HolderPiramal Critical Care B.V.
Licence NumberEU/1/17/1176/001

Group Information

ATC CodeA16AX Various alimentary tract and metabolism products
A16AX06 miglustat

Status

Authorised/WithdrawnAuthorised
Licence Issued22/03/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back